

434
 435
 436
 437
 438

Overall, N = 155	On day 1 of illness				Reported during Initial Visit			
	Total, N = 154	PWH, N = 72	HIV negative, N = 82	SMD	Total N = 154	PWH, N = 72	HIV Negative, N = 82	SMD
Skin lesions	62 (40%)	32 (44%)	30 (37%)	0.16	142 (92%)	68 (93%)	75 (91%)	0.06
Fever	51 (33%)	29 (40%)	22 (27%)	0.29	96 (62%)	47 (64%)	49 (60%)	0.11
Sore throat	11 (7.1%)	4 (5.6%)	7 (8.5%)	0.12	18 (12%)	6 (8.2%)	12 (15%)	0.20
Myalgias	19 (12%)	8 (11%)	11 (13%)	0.07	42 (27%)	15 (21%)	27 (33%)	0.28
Headache	11 (7.1%)	4 (5.6%)	7 (8.5%)	0.12	26 (17%)	8 (11%)	18 (22%)	0.30
Ocular symptom	0 (0%)	0 (0%)	0 (0%)	-	6 (3.9%)	2 (2.7%)	4 (4.9%)	0.11
Fatigue/malaise	29 (19%)	13 (18%)	15 (18%)	0.01	56 (36%)	28 (38%)	29 (35%)	0.04
Oral pain	2 (1.3%)	2 (2.8%)	0 (0%)	0.24	9 (5.8%)	5 (6.8%)	4 (4.9%)	0.09
Odynophagia	0 (0%)	0 (0%)	0 (0%)	-	6 (3.9%)	2 (2.7%)	4 (4.9%)	0.11
Nausea/Vomiting	1 (0.6%)	1 (1.4%)	0 (0%)	0.17	9 (5.8%)	4 (5.5%)	5 (6.1%)	0.02
Diarrhea	3 (1.9%)	2 (2.8%)	1 (1.2%)	0.11	12 (7.8%)	8 (11%)	5 (6.1%)	0.13
Rectal pain	20 (13%)	8 (11%)	12 (15%)	0.11	82 (53%)	34 (47%)	49 (60%)	0.28
Anal bleeding or discharge	8 (5.2%)	7 (9.7%)	1 (1.2%)	0.38	44 (29%)	20 (27%)	25 (30%)	0.09
Dysuria	1 (0.6%)	1 (1.4%)	0 (0%)	0.17	16 (10%)	4 (5.5%)	12 (15%)	0.30
Urethral discharge	1 (0.6%)	1 (1.4%)	0 (0%)	0.17	3 (1.9%)	2 (2.7%)	1 (1.2%)	0.11
Dizziness	0 (0%)	0 (0%)	0 (0%)	-	2 (1.3%)	0 (0%)	2 (2.4%)	0.22
Arthralgia	0 (0%)	0 (0%)	0 (0%)	-	5 (3.2%)	0 (0%)	5 (6.1%)	0.36
Lymphadenopathy	11 (7.1%)	5 (6.9%)	6 (7.3%)	0.01	61 (40%)	20 (27%)	41 (50%)	0.47
Cough/SOB	4 (2.6%)	1 (1.4%)	3 (3.7%)	0.15	10 (6.5%)	4 (5.5%)	6 (7.3%)	0.07
Others	25 (16%)	7 (9.7%)	18 (22%)	0.34	65 (42%)	28 (38%)	37 (45%)	0.13
None of the	0 (0%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	-

above

439 **Supplemental table 1. Clinical presentation of mpox virus infection treated with tecovirimat;**
 440 **symptoms**

441

	Overall (N = 154) n, %	PWH (N = 72) n, %	HIV Negative (N= 82) n, %	Unadjusted SMD
Presence of Prodrôme (N=152)	81 (53%)	34 (49%)	47 (57%)	-0.15
Number of Lesions (N = 151)				
<5	17 (11%)	7 (10%)	10 (12%)	-0.07
5-9	45 (30%)	20 (29%)	25 (30%)	-0.03
10-19	40 (26%)	24 (35%)	16 (20%)	0.35
20-99	46 (30%)	17 (25%)	29 (35%)	-0.24
>= 100	3 (2.0%)	1 (1.4%)	2 (2.4%)	-0.07
Exam Findings (N= 154)				
Lymphadenopathy	42 (27%)	9 (12%)	33 (40%)	-0.66
Pharyngitis	5 (3.2%)	0 (0%)	5 (6.1%)	-0.36
Abdominal Tenderness	1 (0.6%)	0 (0%)	1 (1.2%)	-0.16
Testicular/penile swelling	8 (5.2%)	6 (8.3%)	2 (2.4%)	0.26
Penile Discharge	1 (0.6%)	0 (0%)	1 (1.2%)	-0.16
Perianal tenderness	6 (3.9%)	3 (4.2%)	3 (3.7%)	0.03
Anal discharge or bleeding	1 (0.6%)	1 (1.4%)	0 (0%)	0.17
No non-lesion abnormalities	87 (56%)	47 (65%)	40 (49%)	0.34
Co-occurring STI (N= 154)				
Any STI	48 (31%)	27 (38%)	21 (26%)	0.26
Syphilis	13 (8.4%)	10 (14%)	3 (3.7%)	0.37
Presence of bacterial superinfection	51 (33%)	22 (31%)	29 (37%)	-0.11

442 **Supplemental Table 2: Clinical presentation of mpox virus infection treated with**
 443 **tecovirimat; other findings**

444 STI: sexually transmitted infection

445